PRECIGEN, INC. Fair Value, Assets, Level 2 to Level 1 Transfers, Amount
PRECIGEN, INC. (PGEN) had Fair Value, Assets, Level 2 to Level 1 Transfers, Amount of $0 as of 2015-06-30, per its 10-Q filed 2015-08-10.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount · last filed 2015-08-10
- 2015-06-30: Fair Value, Assets, Level 2 to Level 1 Transfers, Amount $0.00.
| Period end | Fair Value, Assets, Level 2 to Level 1 Transfers, Amount |
|---|---|
| 2015-06-30 | $0.00 10-Q · filed 2015-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |